Angiotensin-converting Enzyme Inhibitors-induced Angioedema

Anca Chiriac 1 , 2 , 3 , Piotr Brzezinski 4 , 5 , 6 , 7 , Mircea Betiu 8 , and Liliana Foia 9
  • 1 Nicolina Medical Center, Department of Dermatology, , Iași, Romania
  • 2 Apollonia University, , Iași, Romania
  • 3 , Iasi
  • 4 Department of Dermatology, 6th Military Support Unit, , Ustka, Poland
  • 5 Department of Dermatology, Provincial Specialist Hospital in Slupsk, , Ustka, Poland
  • 6 Institute of Biology and Environmental Protection, Pomeranian Academy, , Slupsk, Poland
  • 7 Faculty of Mathematics and Natural Sciences, Institute of Biology and Environmental Protection, Pomeranian Academy, , Slupsk, Poland
  • 8 Department of Dermatovenereology, “Nicolae Testemitanu” State University of Medicine and Pharmacy, Chișinău
  • 9 “Grigore T Popa” University of Medicine and Pharmacy, , Iași, Romania

Abstract

Angiotensin-converting enzyme inhibitors (ACEI) are widely used drugs nowadays in treating patients diagnosed with cardiovascular disorders. We present two consecutive cases of acquired angioedema caused by the administration of enalapril and lisinopril in patients with indication for ACE-inhibitors therapy. Rigorous follow-up of side effects of ACEI is required, due to these possible life-threatening adverse reactions.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Korzeniowska K, Cielewiczi A, Pawlaczyk M, Motowidlo K, Andrys-Wawrzyniak I, Jablecka A. Angioedema after angiotensin-converting enzyme inhibitors. Acta Pol Pharm. 2017;74:983-986.

  • 2. Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996;334:1666-1667. doi:10.1056/NEJM199606203342510.

  • 3. Sánchez-Borges M, González-Aveledo L. Angiotensin-Converting Enzyme Inhibitors and Angioedema. Allergy Asthma Immunol Res. 2010;2:195-198. doi: 10.4168/aair.2010.2.3.195.

  • 4. Lewis LM. Angioedema: etiology, pathophysiology, current and emerging therapies. J Emerg Med. 2013;45:789-796. doi: 10.1016/j.jemermed.2013.03.045.

  • 5. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 2007;62:842-56. doi: 10.1111/j.1398-9995.2007.01427.x.

  • 6. Banerji A. Current treatment of hereditary angioedema: An update on clinical studies. Allergy Asthma Proc. 2010;31:398-406. doi: 10.2500/aap.2010.31.3387.

  • 7. Baram M, Kommuri A, Sellers SA, Cohn JR. ACE inhibitorinduced angioedema. J Allergy Clin Immunol Pract. 2013;1:442-445. doi: 10.1016/j.jaip.2013.07.005.

  • 8. Mlynarek A, Hagr A, Kost K. Angiotensin-converting enzyme inhibitor-induced unilateral tongue angioedema. Otolaryngol Head Neck Surg. 2003;129:593-595. doi: 10.1016/S0194-59980300724-1.

  • 9. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624-1630. doi: 10.1161/HYPERTENSIONAHA.108.110270.

  • 10. Cupido C, Rayner B. Life-threatening angio-oedema and death associated with the ACE inhibitor enalapril. S Afr Med J. 2007;97:244-245.

  • 11. Chin HL, Buchan DA. Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor. Ann Intern Med. 1990;112:312-313.

  • 12. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642. doi: 10.1001/archinte.165.14.1637.

  • 13. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensinconverting enzyme inhibitors. J Eval Clin Pract. 2004;10:499-509. doi: 10.1111/j.1365-2753.2003.00484.x.

  • 14. Abbosh J, Anderson JA, Levine AB, Kupin WL. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol. 1999;82:473-476. doi: 10.1016/S1081-1206(10)62723-8.

  • 15. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension. 2008;51:1465-1467. doi: 10.1161/HYPERTENSIONAHA.108.111393.

  • 16. Riedl M. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. Clin Ther. 2012;34:623-630. doi: 10.1016/j.clinthera.2012.02.003.

  • 17. Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72:300-313. doi: 10.1111/all.13001.

  • 18. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10:50. doi: 10.1186/1710-1492-10-50.

  • 19. Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol. 2014;14:354-362. doi: 10.1097/ACI.0000000000000082.

  • 20. Bernstein JA, Moellman JJ. Progress in the emergency management of hereditary angioedema: focus on new treatment options in the United States. Postgrad Med. 2012;124:91-100. doi: 10.3810/pgm.2012.05.2552.

OPEN ACCESS

Journal + Issues

Search